Jornal de Biomarcadores Moleculares e Diagnóstico

Lung Adenocarcinoma with Lymphangitic Carcinomatosis Showing Rapid Response to Anti-PD-1 Immunotherapy: A Brief Report

Abstract

Dothard A, Lycan T and Petty WJ

Lymphangitic carcinomatosis is a difficult to treat disease entity and usually portends a poor prognosis given the advanced state in which it is often diagnosed. Treatment is usually based on standard therapy of the primary malignancy, but in most cases, is palliative in nature. This case highlights the potential for PD-1 immunotherapy as both a rapid and durable treatment for lymphangitic carcinomatosis.